- Home
- LUCY vs ACON Comparison
LUCY vs ACON Comparison
Compare LUCY & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | ACON |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | 13 | 11 |
| Industry | Ophthalmic Goods | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCY | ACON |
|---|---|---|
| Price | $0.76 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 58.1K | ★ 83.8K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $175.92 | $87.22 |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $2.34 |
| 52 Week High | $2.39 | $12.03 |
Technical Indicators
Market Signals| Indicator | LUCY | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 32.48 | 38.08 |
| Support Level | N/A | $2.38 |
| Resistance Level | $1.17 | $3.54 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 44.72 | 22.83 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.